Comprehensive Assessment of Neurodegeneration and Dementia

The Comprehensive Assessment of Neurodegeneration and Dementia Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03402919

Acronym

COMPASS-ND

Enrollment

1573

Registered

2018-01-18

Start date

2016-06-01

Completion date

2029-12-01

Last updated

2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease (AD), Cognitively Unimpaired, Dementia, Frontotemporal Dementia (FTD), Lewy Body Disease(LBD), Mild Cognitive Impairment (MCI), Mixed Dementia, Parkinson's Disease (PD), Subjective Cognitive Decline (SCD), Subjective Cognitive Impairment

Keywords

Observational, Dementia, Alzheimer's Disease, Parkinson's Disease, Biosample, Genetics, Neuropsychological, MRI, Microbiome, Plasma

Brief summary

This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are/will be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.

Detailed description

This is a longitudinal observational study that started in Phase I with the recruitment of 1173 participants between the ages of 50 and 90 years with Subjective Cognitive Impairment, Mild Cognitive Impairment, Mild Cognitive Impairment with subcortical vascular lesions, Alzheimer's Disease, Mixed dementia, Lewy Body Dementia, Parkinson's Disease Dementia, Parkinson's Disease with Mild Cognitive Impairment and Frontotemporal Dementia as well as healthy elderly subjects without cognitive complaints or deficits. These participants were enrolled in 30 different centres across Canada. All subjects involved in the study underwent rigorous evaluations at baseline, including clinical assessment, neuropsychological assessment, genomics and neuroimaging. Biological samples from blood, saliva, urine, fecal matter, buccal cells and cerebrospinal fluid were collected, stored, and analyzed. Longitudinal follow-up determining if there has been any change in their diagnosis was carried out annually and longitudinal re-evaluation was carried out at two times: Time 2 and Time 3. In Time 3, 400 participants across the non-dementia cohorts (Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Mild Cognitive Impairment with a Vascular Component, Parkinson's Disease with no Cognitive Impairment, Parkinson's Disease with Mild Cognitive Impairment) with up to 12 years of education will be recruited.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* Has subjective or objective cognitive impairment * Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver/family member) * Sufficient proficiency in English or French to undertake self report and neuropsychological testing * Geographic accessibility to the study site * Must have a study partner who can participate as required in the protocol (provide corroborative information) * Up to 12 years of education * Fits into one of the following groups: Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Vascular Mild Cognitive Impairment, Parkinson's Disease, Parkinson's Disease with Mild Cognitive Impairment

Exclusion criteria

* The presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease (other than for the Parkinson's cohort), and other rarer brain illnesses * Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures * Symptomatic stroke within the previous year * Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure

Design outcomes

Primary

Measure	Time frame	Description
Montreal Cognitive Assessment (MoCA) score	8 years	change in MoCA total score. The MoCA is a test of global cognition scored out of 30 with a higher score indicating better performance. The minimum score is 0 and the maximum score is 30.

Countries

Canada

Contacts

CONTACTHoward Chertkow, MD

howard.chertkow@mcgill.ca514 340 8222

CONTACTRandi Pilon

Randi.Pilon@ladydavis.ca514 8339709

STUDY_DIRECTORMichael Borrie, MD

Western University

STUDY_DIRECTORNatalie Philips, PhD

Concordia University, Montreal

STUDY_DIRECTORJaspreet Bhangu, MB